Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NEU2 | Q9Y3R4 | 2/20 | 0.45 |
| ▸ | NEU4 | Q8WWR8 | 1/20 | 0.45 |
| ▸ | NEU3 | Q9UQ49 | 1/20 | 0.45 |
| ▸ | NANP | Q8TBE9 | 3/20 | 0.45 |
| ▸ | SIGLEC7 | Q9Y286 | 6/20 | 0.35 |
| ▸ | CD22 | P20273 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16362516 | 0.93 | NEU2 (0.47) | NEU2NEU4NEU3NANPSIGLEC7 | |
| SCHEMBL24629707 | 0.93 | CD22 (0.41) | NEU2NEU4NEU3NANPCD22 | |
| SCHEMBL27390999 | 0.93 | NEU2 (0.39) | NEU2NEU4NEU3NANPCD22 | |
| SCHEMBL29727740 | 0.92 | NEU2 (0.38) | NEU2NEU4NEU3NANPCD22 | |
| SCHEMBL31695063 | 0.91 | NEU2 (0.37) | NEU2NEU4NEU3NANPCD22 | |
| SCHEMBL31226018 | 0.91 | NEU2 (0.37) | NEU2NEU4NEU3NANPCD22 | |
| SCHEMBL24629706 | 0.88 | NEU2 (0.37) | NEU2NEU4NEU3NANP | |
| SCHEMBL24630167 | 0.88 | NANP (0.47) | NEU2NEU4NEU3NANPSIGLEC7 | |
| SCHEMBL29325979 | 0.88 | NANP (0.47) | NANPCD22 | |
| SCHEMBL31225460 | 0.84 | NEU2 (0.39) | NEU2NEU4NEU3CD22 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4727537-A2 | SIGLEC LIGANDS, CONJUGATES, AND METHODS OF USE THEREOF | Adaxion Therapeutics, Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| EP-4554622-A2 | AUTOANTIGENS ENGINEERED TO SUPPRESS AUTOIMMUNE RESPONSE | Osprey Biopharmaceuticals, Inc. (US) | 2025-05-21 | — | — | EP | disclosed |
| US-20250127904-A1 | SIGLEC LIGANDS, CONJUGATES, AND METHODS OF USE THEREOF | ADAXION THERAPEUTICS, INC. | 2025-04-24 | — | — | US | disclosed |
| WO-2025076427-A1 | SIGLEC LIGANDS, CONJUGATES, AND METHODS OF USE THEREOF | OSPREY BIOPHARMACEUTICALS, INC. (US) | 2025-04-10 | — | — | WO | disclosed |
| US-20250064941-A1 | SIGLEC LIGANDS, CONJUGATES, AND METHODS OF USE THEREOF | ADAXION THERAPEUTICS, INC. | 2025-02-27 | — | — | US | disclosed |
| WO-2024259007-A2 | SIGLEC LIGANDS, CONJUGATES, AND METHODS OF USE THEREOF | OSPREY BIOPHARMACEUTICALS, INC. (US) | 2024-12-19 | — | — | WO | disclosed |
| US-20240238422-A1 | Hypoimmunogenic Biotherapeutics | ADAXION THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
| US-20240238422-A1 | Hypoimmunogenic Biotherapeutics | ADAXION THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
| US-20240238422-A1 | Hypoimmunogenic Biotherapeutics | ADAXION THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
| US-20240216490-A1 | Autoantigens Engineered to Suppress Autoimmune Response | ADAXION THERAPEUTICS, INC. | 2024-07-04 | — | — | US | disclosed |
| US-20240216490-A1 | Autoantigens Engineered to Suppress Autoimmune Response | ADAXION THERAPEUTICS, INC. | 2024-07-04 | — | — | US | disclosed |
| WO-2024015872-A2 | AUTOANTIGENS ENGINEERED TO SUPPRESS AUTOIMMUNE RESPONSE | OSPREY BIOPHARMACEUTICALS, INC. (US) | 2024-01-18 | — | — | WO | disclosed |
| WO-2024015872-A2 | AUTOANTIGENS ENGINEERED TO SUPPRESS AUTOIMMUNE RESPONSE | OSPREY BIOPHARMACEUTICALS, INC. (US) | 2024-01-18 | — | — | WO | disclosed |
| EP-4274582-A1 | HYPOIMMUNOGENIC BIOTHERAPEUTICS | Osprey Biopharmaceuticals, Inc. (US) | 2023-11-15 | — | — | EP | disclosed |
| WO-2022150726-A1 | HYPOIMMUNOGENIC BIOTHERAPEUTICS | OSPREY BIOPHARMACEUTICALS, INC. (US) | 2022-07-14 | — | — | WO | disclosed |
| WO-2022150726-A1 | HYPOIMMUNOGENIC BIOTHERAPEUTICS | OSPREY BIOPHARMACEUTICALS, INC. (US) | 2022-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250127904-A1 | SIGLEC LIGANDS, CONJUGATES, AND METHODS OF USE THEREOF | SIGLEC7, SIGLEC9, SELPLG | NEU2 24/4885NEU4 25/4885NEU3 15/4885 |
| US-20240216490-A1 | Autoantigens Engineered to Suppress Autoimmune Response | CD74, MICA, HLA-DRB1 | NEU2 1464/4885NEU4 1306/4885NEU3 1553/4885 |
| US-20250064941-A1 | SIGLEC LIGANDS, CONJUGATES, AND METHODS OF USE THEREOF | SIGLEC7, SIGLEC9, CD2BP2 | NEU2 43/4885NEU4 42/4885NEU3 41/4885 |
| US-20240238422-A1 | Hypoimmunogenic Biotherapeutics | FCGR3B, CD47, IL2 | NEU2 429/4885NEU4 1203/4885NEU3 762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.